Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$48.37 USD
-0.48 (-0.98%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $48.17 -0.20 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AKRO 48.37 -0.48(-0.98%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Other News for AKRO
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Insider Sell: Andrew Cheng Sells 30,000 Shares of Akero Therapeutics Inc (AKRO)
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Target | AKRO Stock News